Binghe Xu Selected Research

Vinorelbine (Navelbine)

7/2021	Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
5/2021	Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA.
1/2021	Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.
1/2021	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective.
1/2019	Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
3/2016	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
10/2015	Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial.
10/2015	Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment.
10/2015	[Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
5/2014	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Binghe Xu Research Topics

Disease

143	Breast Neoplasms (Breast Cancer) 06/2022 - 11/2007
63	Neoplasms (Cancer) 06/2022 - 05/2008
39	Triple Negative Breast Neoplasms 02/2022 - 01/2013
19	Disease Progression 01/2022 - 11/2007
17	Neoplasm Metastasis (Metastasis) 02/2022 - 08/2012
17	Neutropenia 01/2022 - 11/2007
8	Diarrhea 03/2021 - 06/2013
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2009
6	Lymphatic Metastasis 01/2021 - 10/2010
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2014 - 11/2002
5	Hand-Foot Syndrome 03/2021 - 10/2019
5	Stomach Neoplasms (Stomach Cancer) 01/2017 - 03/2015
5	Lung Neoplasms (Lung Cancer) 01/2014 - 05/2008
4	Leukopenia 11/2021 - 05/2015
4	Carcinogenesis 05/2021 - 05/2008
4	Exanthema (Rash) 12/2020 - 09/2014
4	Nausea 10/2019 - 09/2017
3	Pneumonia (Pneumonitis) 01/2022 - 01/2018
3	Cardiotoxicity 01/2022 - 12/2014
3	Hypertension (High Blood Pressure) 03/2021 - 05/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 03/2021 - 12/2018
3	Circulating Neoplastic Cells 01/2021 - 10/2016
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 01/2017
3	Febrile Neutropenia 01/2020 - 05/2014
3	Pathologic Complete Response 01/2019 - 04/2016
3	Esophageal Neoplasms (Esophageal Cancer) 01/2019 - 03/2015
3	Fatigue 01/2018 - 11/2007
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 01/2022
2	Thrombocytopenia (Thrombopenia) 01/2022 - 07/2021
2	Ductal Carcinoma 10/2021 - 01/2021
2	Brain Neoplasms (Brain Tumor) 02/2021 - 09/2014
2	Hypoxia (Hypoxemia) 01/2021 - 03/2016

Drug/Important Bio-Agent (IBA)

32	Hormones (Hormone)IBA 06/2022 - 01/2011
32	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2013
31	AnthracyclinesIBA 01/2022 - 11/2007
27	human ERBB2 proteinIBA 04/2022 - 09/2012
23	Capecitabine (Xeloda)FDA Link 01/2021 - 11/2007
21	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 12/2010
19	taxaneIBA 01/2022 - 11/2007
18	Taxoids (Taxanes)IBA 03/2021 - 11/2007
17	ErbB Receptors (EGF Receptor)IBA 12/2021 - 06/2013
15	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2008
14	PlatinumIBA 02/2022 - 05/2008
12	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 09/2012
12	Lapatinib (GW572016)FDA Link 01/2021 - 01/2013
11	Vinorelbine (Navelbine)FDA LinkGeneric 07/2021 - 01/2010
10	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 01/2013
9	Phenobarbital (Luminal)FDA Link 02/2022 - 12/2013
9	Estrogen ReceptorsIBA 10/2021 - 01/2013
8	Proteins (Proteins, Gene)FDA Link 06/2022 - 10/2008
8	Indicators and Reagents (Reagents)IBA 06/2022 - 10/2016
8	Docetaxel (Taxotere)FDA Link 01/2022 - 05/2014
8	Pharmaceutical PreparationsIBA 01/2022 - 07/2011
8	Aromatase InhibitorsIBA 01/2020 - 01/2011
7	Circulating Tumor DNAIBA 01/2022 - 01/2017
7	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 07/2011
7	pyrotinibIBA 01/2021 - 09/2017
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 09/2012
6	ixabepilone (BMS 247550)FDA Link 08/2012 - 11/2007
5	Fulvestrant (Faslodex)FDA Link 11/2021 - 01/2011
5	DNA (Deoxyribonucleic Acid)IBA 02/2021 - 10/2008
5	camrelizumabIBA 02/2019 - 01/2018
4	Epidermal Growth Factor (EGF)IBA 01/2022 - 04/2016
4	Letrozole (Femara)FDA LinkGeneric 10/2021 - 01/2011
4	Everolimus FDA Link 10/2021 - 05/2014
4	Biological ProductsIBA 05/2021 - 09/2014
4	apatinibIBA 05/2021 - 10/2014
4	pertuzumabIBA 03/2021 - 01/2019
4	MicroRNAs (MicroRNA)IBA 01/2018 - 08/2011
4	Tyrosine Kinase InhibitorsIBA 09/2017 - 04/2014
4	Cisplatin (Platino)FDA LinkGeneric 12/2015 - 10/2008
4	Gemcitabine FDA Link 12/2014 - 12/2010
3	Immune Checkpoint InhibitorsIBA 01/2022 - 03/2016
3	Cyclin-Dependent Kinase 4IBA 11/2021 - 04/2021
3	exemestane (Aromasin)FDA Link 01/2021 - 04/2014
3	olaparibIBA 01/2020 - 10/2017
3	neratinibIBA 10/2019 - 11/2014
3	Tamoxifen FDA LinkGeneric 01/2019 - 01/2018
2	Type II DNA Topoisomerases (Topoisomerase II)IBA 06/2022 - 01/2017
2	Ado-Trastuzumab EmtansineIBA 01/2022 - 07/2021
2	trastuzumab deruxtecanIBA 01/2022 - 01/2022
2	AntibodiesIBA 01/2022 - 01/2019
2	LigandsIBA 12/2021 - 03/2016
2	dalpiciclibIBA 11/2021 - 04/2021
2	TOR Serine-Threonine KinasesIBA 10/2021 - 05/2019
2	RNA (Ribonucleic Acid)IBA 05/2021 - 01/2020
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2021 - 01/2016
2	TensinsIBA 02/2021 - 07/2014
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 02/2021 - 07/2014
2	eribulin FDA Link 01/2021 - 01/2019

Therapy/Procedure

64	Therapeutics 02/2022 - 11/2002
61	Drug Therapy (Chemotherapy) 02/2022 - 05/2008
16	Neoadjuvant Therapy 02/2022 - 09/2012
14	Adjuvant Chemotherapy 01/2022 - 01/2015
3	Immunotherapy 01/2022 - 01/2019
3	Aftercare (After-Treatment) 01/2022 - 11/2014
3	Radiotherapy 12/2021 - 10/2010
2	Palliative Care (Palliative Therapy) 02/2022 - 08/2020
2	Lymph Node Excision (Lymph Node Dissection) 10/2021 - 08/2016
2	Mastectomy (Mammectomy) 10/2021 - 07/2017